ReviewNature reviews. Rheumatology2023
Juvenile idiopathic inflammatory myositis: an update on pathophysiology and clinical care.
Review in Nature reviews. Rheumatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 65 citations in OpenAlex.
- IFN-related gene expression defines disease activity, organ involvement and treatment response in JDM.Rheumatology (Oxford, England) · 2026Article
- Comorbidities in Juvenile-Onset Rheumatic Diseases: A Systematic Review and Meta-Analysis.Children (Basel, Switzerland) · 2026Review
- Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive Juvenile Dermatomyositis Presenting With Predominant Joint Contractures.Revista de neurologia · 2026Article
- Article
- Tissue calcinosis in dermatomyositis - potential role of combination therapy with JAK inhibitors. Case report and literature review.Frontiers in immunology · 2026Review
- Progress of biological agents and CAR cell therapy in the treatment of common autoimmune diseases in children.Frontiers in pediatrics · 2026Review
- Prognostic Implications of Myositis-Specific Autoantibodies on Mortality, Relapse, and Remission in Dermatomyositis Patients.European journal of neurology · 2025Article
- Advances in JDM: biomarker and MRI sensitivity, outcomes and steroid management in a Dutch national prospective cohort.Rheumatology (Oxford, England) · 2025Article
- Imaging evaluation of rheumatologic musculoskeletal disorders in children.Skeletal radiology · 2025Review
- Immune-Mediated Necrotizing Myopathy Diagnosis and Flare in an Adolescent After COVID-19 Vaccine.Clinical case reports · 2025Article
- Nailfold videocapillaroscopy in juvenile dermatomyositis: detailed correlations between microvascular abnormalities with clinical and laboratory parameters from an observational retrospective single-center study.Clinical rheumatology · 2025Observational
- Approach to Janus kinase inhibition for juvenile dermatomyositis among CARRA and PReS providers.Rheumatology (Oxford, England) · 2025Article
- Calcinosis Universalis: An Atypical Presentation of Mi-2 Positive Juvenile Dermatomyositis - A Case-Based Review.Mediterranean journal of rheumatology · 2025Article
- Interferon Response Gene Score in Juvenile Dermatomyositis.The Journal of rheumatology · 2025Article
- CAR-T cell therapy for juvenile-onset autoimmune diseases: a promising future?Arthritis research & therapy · 2025Review
- Idiopathic Inflammatory Myopathies: Recent Evidence Linking Pathogenesis and Clinical Features.International journal of molecular sciences · 2025Review
- Successful treatment of an anti-MDA5 antibody-positive Juvenile Dermatomyositis patient with refractory interstitial lung disease using tofacitinib.Pediatric rheumatology online journal · 2025Article
- Anti-nuclear Matrix Protein 2 Antibody-Positive Dermatomyositis Relapse With Preceding Panniculitis.Cureus · 2025Article
- An update on autoantibodies in the idiopathic inflammatory myopathies.Nature reviews. Rheumatology · 2025Review
- Juvenile Dermatomyositis: Updates in Pathogenesis and Biomarkers, Current Treatment, and Emerging Targeted Therapies.Paediatric drugs · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
Abstract
The childhood-onset or juvenile idiopathic inflammatory myopathies (JIIMs) are a heterogenous group of rare and serious autoimmune diseases of children and young people that predominantly affect the muscles and skin but can also involve other organs, including the lungs, gut, joints, heart and central nervous system. Different myositis-specific autoantibodies have been identified that are associated with different muscle biopsy features, as well as with different clinical characteristics, prognoses and treatment responses. Thus, myositis-specific autoantibodies can be used to subset JIIMs into sub-phenotypes; some of these sub-phenotypes parallel disease seen in adults, whereas others are distinct from adult-onset idiopathic inflammatory myopathies. Although treatments and management have much improved over the past decade, evidence is still lacking for many of the current treatments and few validated prognostic biomarkers are available with which to predict response to treatment, comorbidities (such as calcinosis) or outcome. Emerging data on the pathogenesis of the JIIMs are leading to proposals for new trials and tools for monitoring disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.